Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Use of prior knowledge and extrapolation in paediatric drug development: A case study with deferasirox.

Borella E, Oosterholt S, Magni P, Pasqua OD.

Eur J Pharm Sci. 2019 May 17. pii: S0928-0987(19)30186-1. doi: 10.1016/j.ejps.2019.05.009. [Epub ahead of print]

PMID:
31108206
2.

Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome.

Glaze DG, Neul JL, Kaufmann WE, Berry-Kravis E, Condon S, Stoms G, Oosterholt S, Della Pasqua O, Glass L, Jones NE, Percy AK; Rett 002 Study Group.

Neurology. 2019 Apr 16;92(16):e1912-e1925. doi: 10.1212/WNL.0000000000007316. Epub 2019 Mar 27.

PMID:
30918097
3.

Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura.

Taylor A, Vendramin C, Oosterholt S, Della Pasqua O, Scully M.

J Thromb Haemost. 2019 Jan;17(1):88-98. doi: 10.1111/jth.14345. Epub 2018 Dec 31.

PMID:
30475428
4.

Population pharmacokinetics of NNZ-2566 in healthy subjects.

Oosterholt SP, Horrigan J, Jones N, Glass L, Della Pasqua O.

Eur J Pharm Sci. 2017 Nov 15;109S:S98-S107. doi: 10.1016/j.ejps.2017.05.032. Epub 2017 May 15.

PMID:
28522374
5.

Biomarker exposure-response relationships as the basis for rational dose selection: Lessons from a simulation exercise using a selective COX-2 inhibitor.

Taneja A, Oosterholt SP, Danhof M, Della Pasqua O.

J Clin Pharmacol. 2016 May;56(5):609-21. doi: 10.1002/jcph.629. Epub 2015 Dec 27.

PMID:
26331692

Supplemental Content

Loading ...
Support Center